Study summary
A bispecific antibody alone beat standard treatment at first relapse
69.8%progression-free at 18 months, vs 26.9% with standard treatment
What was tested
Teclistamab, a bispecific antibody that links T cells to myeloma cells, against standard combination therapy, for myeloma after 1 to 3 earlier treatments.
What they found
- At 18 months, 69.8% were progression-free vs 26.9% with standard treatment.
- 79.2% vs 68.6% were alive at 18 months.
- Serious infections were more common (41.6% vs 29.0%).
What it means
Teclistamab alone outperformed standard combination chemotherapy even used this early, though infection risk needs managing.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.